Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus AZMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus AZMACORT.
ARMONAIR RESPICLICK vs AZMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid